Wall Street Analysts Turn Bullish on 3 Promising Biotech Stocks (Buy Ratings)
Analysts see big upside in UroGen, Rapport, and Milestone, driven by strong drugs, upcoming data, and underestimated market potential.
/ 2 items
Analysts see big upside in UroGen, Rapport, and Milestone, driven by strong drugs, upcoming data, and underestimated market potential.
Milestone's (MIST) CARDAMYST nasal spray is FDA-approved for adults with PSVT (fast heart rate episodes). It's the first quick, self-administered home treatment.